
Boomerang Ventures Makes Seed-Stage Investment in SynchNeuro to Advance Brain-Based Non-Invasive Glucose Monitoring Technology
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a pioneering neurotechnology company developing the world’s first brain-based, non-invasive continuous glucose monitor. The partnership accelerates SynchNeuro’s mission to revolutionize cardiometabolic health through EEG-based technology that interprets brain signals to track blood glucose and other vital metrics in real time. This innovative approach aims to make proactive, pain-free, and affordable glucose monitoring accessible to millions.








